Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC) Fair Value & Analysis
Healthcare · VN · Market cap 428B VND
Fair value as of: Jun 24, 2026
Analysis
Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC) currently trades at 3,660 VND, while our model-based Fair Value estimate is 6,454 VND — implying the stock looks roughly 76.3% undervalued today. We read business quality at 81/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Vietnam Medical and Pharmaceutical Investment Joint Stock Company engages in the distribution of medical equipment and instruments in Vietnam. The company distributes medical equipment, including diagnostic imaging products, such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray system, computed and direct radiography, dry imager, contrast injector, PET/CT imaging system, and diagnostic ultrasound products; washers, dryers, and sterilizers; and ultrasound systems, anesthesia and breathing machines, syringe and infusion pumps, and patient monitors, as well as navigation products. It also offers SD-S, DI-HT, SD-Q, and DI-HL dry medical films; central venous catheters and invasive blood pressure transducers for resuscitation-cardiovascular intervention; Scepter XC and C balloon, and Chaperon guiding catheters; LVIS Jr. and LVIS coil assist stents; and V-grip detachment controllers, Traxcess guidewires, Headway Duo microcatheters, ERIC retrieval devices, SOFIA PLUS as…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Vietnam Medical and Pharmaceutical Investment Joint Stock Company (JVC) undervalued?
What is the fair value of JVC?
What is the quality score of JVC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.